| Dr John Manning Carson, MD | |
|
200 Old Country Rd Ste 135, Mineola, NY 11501-4237 | |
| (516) 663-2169 | |
| (516) 663-2179 |
| Full Name | Dr John Manning Carson |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 16 Years |
| Location | 200 Old Country Rd Ste 135, Mineola, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578724787 | NPI | - | NPPES |
| 023865 | Other | CO | KAISER COMMERCIAL NUMBER |
| 80284272 | Medicaid | CO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 291345 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| New York University Langone Medical Center | New york, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| New York University | 1355232422 | 4431 |
News Archive
According to findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery significantly improves disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations.
Many approved cancer therapies target a protein called epidermal growth factor receptor (EGFR) that regulates many crucial cellular processes and can speed the proliferation of tumor cells.
The Telegraph reports that when "UNICEF began publishing prices agreed with suppliers for a range of vaccines over the past decade, ... some companies - including GSK, Novartis, Intervax and Crucell - did not initially allow disclosure."
African American children living in socioeconomically disadvantaged neighborhoods are significantly less likely than their Caucasian counterparts in disadvantaged or wealthier areas to receive CPR from a bystander, according to new research in Journal of the American Heart Association,the Open Access Journal of the American Heart Association/American Stroke Association.
Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review of the Biologics License Application (BLA) for the investigational agent ZALTRAP (aflibercept) concentrate for solution for infusion in combination with the irinotecan-fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-containing regimen.
› Verified 6 days ago
| Entity Name | New York University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285826438 PECOS PAC ID: 1355232422 Enrollment ID: O20090822000026 |
News Archive
According to findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery significantly improves disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations.
Many approved cancer therapies target a protein called epidermal growth factor receptor (EGFR) that regulates many crucial cellular processes and can speed the proliferation of tumor cells.
The Telegraph reports that when "UNICEF began publishing prices agreed with suppliers for a range of vaccines over the past decade, ... some companies - including GSK, Novartis, Intervax and Crucell - did not initially allow disclosure."
African American children living in socioeconomically disadvantaged neighborhoods are significantly less likely than their Caucasian counterparts in disadvantaged or wealthier areas to receive CPR from a bystander, according to new research in Journal of the American Heart Association,the Open Access Journal of the American Heart Association/American Stroke Association.
Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review of the Biologics License Application (BLA) for the investigational agent ZALTRAP (aflibercept) concentrate for solution for infusion in combination with the irinotecan-fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-containing regimen.
› Verified 6 days ago
| Entity Name | Winthrop Community Medical Affiliates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457873077 PECOS PAC ID: 5698092385 Enrollment ID: O20150317001669 |
News Archive
According to findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery significantly improves disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations.
Many approved cancer therapies target a protein called epidermal growth factor receptor (EGFR) that regulates many crucial cellular processes and can speed the proliferation of tumor cells.
The Telegraph reports that when "UNICEF began publishing prices agreed with suppliers for a range of vaccines over the past decade, ... some companies - including GSK, Novartis, Intervax and Crucell - did not initially allow disclosure."
African American children living in socioeconomically disadvantaged neighborhoods are significantly less likely than their Caucasian counterparts in disadvantaged or wealthier areas to receive CPR from a bystander, according to new research in Journal of the American Heart Association,the Open Access Journal of the American Heart Association/American Stroke Association.
Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review of the Biologics License Application (BLA) for the investigational agent ZALTRAP (aflibercept) concentrate for solution for infusion in combination with the irinotecan-fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-containing regimen.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John Manning Carson, MD 200 Old Country Rd Ste 135, Mineola, NY 11501-4237 Ph: (516) 663-2169 | Dr John Manning Carson, MD 200 Old Country Rd Ste 135, Mineola, NY 11501-4237 Ph: (516) 663-2169 |
News Archive
According to findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery significantly improves disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations.
Many approved cancer therapies target a protein called epidermal growth factor receptor (EGFR) that regulates many crucial cellular processes and can speed the proliferation of tumor cells.
The Telegraph reports that when "UNICEF began publishing prices agreed with suppliers for a range of vaccines over the past decade, ... some companies - including GSK, Novartis, Intervax and Crucell - did not initially allow disclosure."
African American children living in socioeconomically disadvantaged neighborhoods are significantly less likely than their Caucasian counterparts in disadvantaged or wealthier areas to receive CPR from a bystander, according to new research in Journal of the American Heart Association,the Open Access Journal of the American Heart Association/American Stroke Association.
Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review of the Biologics License Application (BLA) for the investigational agent ZALTRAP (aflibercept) concentrate for solution for infusion in combination with the irinotecan-fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-containing regimen.
› Verified 6 days ago
Dr. Marlene Martins Lobato, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 173 Mineola Blvd, Suite 403, Mineola, NY 11501 Phone: 516-741-8891 Fax: 516-741-8829 | |
Michael Garrison, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 200 Old Country Rd, Suite 450, Mineola, NY 11501 Phone: 516-663-9500 Fax: 516-663-4613 | |
Dr. Anupama Ananda, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 190 Willis Ave, Suite 210, Mineola, NY 11501 Phone: 516-739-7290 Fax: 516-793-7291 | |
Mr. Jeffrey Liu, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 297 Mineola Blvd, Mineola, NY 11501 Phone: 516-294-1377 Fax: 516-294-5574 | |
Dr. Jonathan Shulman, D.O. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 259 1st St, Mineola, NY 11501 Phone: 516-663-2381 | |
John I Hogan, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 222 Station Plz N Ste 432, Mineola, NY 11501 Phone: 516-663-2507 | |
Dr. Anthony Massimillo, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 300 Old Country Rd Ste 31, Mineola, NY 11501 Phone: 516-294-9380 Fax: 516-294-5351 |